Richard young 2023

Richard Young

Managing Director and Principal Toxicologist

UKRT/ERT

Richard has >20 years’ experience in desk-based toxicology at bibra. He has an MSc in Applied Toxicology and is a RSB/BTS and European Registered Toxicologist (ERT). His skills include expert analysis of human health data. This can involve the pragmatic application of risk assessment methodology to mammalian toxicity data sets in order to derive robust conclusions on toxicological acceptability and health risks to exposed populations. In 2018, Richard became the Managing Director of bibra.

Richard has worked for clients from the food and beverage, food contact materials, consumer goods, agrochemical, biocidal, industrial chemical, pharmaceutical, electronic cigarette and cannabinoid sectors. For the past 15 years, he has been heavily involved in assisting companies comply with their REACH registration obligations, including supporting registrants respond to ECHA Evaluation decisions. Richard has played a key role in assisting e-cigarette and e-liquid manufacturers and importers with the toxicological assessments of their products, notably with their EU TPD and US FDA PMTA compliance obligations. Most recently he has been involved in the toxicological assessment of cannabinoids (notably CBD and THC) for a number of clients from a range of sectors (e.g. food, consumer products and pharmaceuticals).

In his spare time Richard can be found playing padel tennis and 5-a-side football (when his knees can cope), and running around and entertaining his two children.

Richard's case studies and blog posts

FDA memoranda: shedding light on health risk assessment of ENDS in PMTA submissions

Blog articles

In 2016, the United States (US) Food and Drug Administration (FDA) ruled that Electronic Nicotine Delivery Systems (ENDS) were to be regulated just like more traditional tobacco products, meaning that ENDS (e-cigarettes and e-liquids) are subject to premarket review requirements, despite containing no tobacco. ENDS manufacturers must therefore submit a Premarket Tobacco Product Application (PMTA) to the FDA Center for Tobacco Products (CTP) in order to have any chance of legally marketing their products in the US.

Updating REACH dossiers following ECHA Evaluation decisions

Case study

Manufacturers of chemicals in, or importers into, the European Union are required under the REACH regulation to submit a dossier of information on their substances to the European Chemicals Agency (ECHA). The Agency can, after evaluating the information provided by the registrant, require the company to update or amend their dossier, including with the addition of new experimental data. This is called a “Compliance Check decision”

FDA memoranda: genotoxicity and carcinogenicity assessments of ENDS

Blog articles

As discussed in a previous blog post, the U.S. Food and Drug Administration (FDA) Center for Tobacco Products (CTP) has issued several “scientific policy memoranda” that provide some great insights into the Agency’s evaluation process. In June 2024, the FDA made two new memos available that relate to the genotoxicity and carcinogenicity assessment of chemical constituents of Electronic Nicotine Delivery Systems (ENDS).

Want to read more case studies and blog posts that Richard has been involved in? Click below to read more.

Contact us